XML 61 R39.htm IDEA: XBRL DOCUMENT v3.24.0.1
Sale of Pelican Business and Investment in Primrose Bio - Narrative (Details)
$ in Thousands
 12 Months Ended
Sep. 18, 2023
USD ($)
contract
shares
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Jan. 01, 2025
USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations          
Gain on sale of business   $ 2,121 $ 0 $ 0  
Derivative assets with fair value $ 3,200        
Derivative Asset Noncurrent, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag   consolidated balance sheet      
Net loss from discontinued operations   $ 1,665 $ 28,142 $ 19,215  
Gain on derivative instruments   300      
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Pelican Technology Holdings, Inc.          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations          
Consideration paid for an interest in potential development milestone 15,000        
Goodwill written off   4,100      
Gain on sale of business   2,100      
Business exit costs $ 1,200        
Net loss from discontinued operations   $ 1,800      
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Pelican Technology Holdings, Inc. | Restricted stock          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations          
Shares received as consideration | shares 474,746        
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Pelican Technology Holdings, Inc. | Common Stock          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations          
Shares received as consideration | shares 2,146,957        
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Pelican Technology Holdings, Inc. | Preferred Stock          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations          
Shares received as consideration | shares 4,278,293        
Primrose Bio          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations          
Consideration paid for an interest in potential development milestone $ 15,000        
Interest in potential development milestone (as a percent) 50.00%        
Forecast | Primrose Bio | PeliCRM197          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations          
Sales revenue milestone         $ 3,000
Forecast | Primrose Bio | PeliCRM197 | Below 3 million          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations          
Interest in sales revenue (as a percent)         25.00%
Forecast | Primrose Bio | PeliCRM197 | Above 3 million          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations          
Interest in sales revenue (as a percent)         35.00%
Primordial Genetics          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations          
Number of contracts | contract 2